Start › Rak piersi › Wirginia › Arlington
Badania kliniczne dla Rak piersi w mieście Arlington, VA
46 badań dla Rak piersi szuka uczestników w ośrodkach w mieście Arlington i okolicach (w promieniu ok. 30 mil). Otwórz badanie, aby zobaczyć kryteria kwalifikacji i dane kontaktowe zespołu badawczego.
Oficjalny tekst badania (angielski)
Rekrutujesz uczestników do badania? Wyróżnij je na górze tej strony – $99 za 30 dni →
The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
RekrutacjaFaza 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi dalej
A Phase 2 Neoadjuvant Study of Zanidatamab in Combination With Chemotherapy in Participants With HER2-positive Breast Cancer
RekrutacjaFaza 2
- Virginia Cancer Specialists, Fairfax · 11 mi dalej
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RekrutacjaFaza 1/2
- Inova Schar Cancer Institute, Fairfax · 11 mi dalej
- Virginia Cancer Specialists, PC, Fairfax · 11 mi dalej
Conventionally Fractionated vs. Hypofractionated Comprehensive Nodal Irradiation for Breast Cancer Using Pencil Beam Scanning Proton Therapy
RekrutacjaFaza 3
- Inova Schar Cancer Institute, Fairfax · 11 mi dalej
Phase II Protocol of Proton Therapy for Partial Breast Irradiation in Early Stage Breast Cancer
RekrutacjaFaza 2
- Inova Schar Cancer Institute, Fairfax · 11 mi dalej
Study of AVZO-021 in Patients With Advanced Solid Tumors
RekrutacjaFaza 1/2
- Avenzo Therapeutics Recruiting Site, Fairfax · 11 mi dalej
A Study of Sacituzumab Tirumotecan (MK-2870) as a Single Agent and in Combination With Pembrolizumab (MK-3475) Versus Treatment of Physician's Choice in Participants With HR+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer (MK-2870-010)
RekrutacjaFaza 3
- Inova Schar Cancer Institute ( Site 0025), Fairfax · 11 mi dalej
A Phase III Study of Dato-DXd With or Without Durvalumab Compared With Investigator's Choice of Chemotherapy in Combination With Pembrolizumab in Patients With PD-L1 Positive Locally Recurrent Inoperable or Metastatic Triple-negative Breast Cancer (TROPION-Breast05)
RekrutacjaFaza 3
- Research Site, Fairfax · 11 mi dalej
ASPEN-09-03: A Study of Evorpacept in Combination With Trastuzumab and Chemotherapy in Metastatic HER2-Positive Breast Cancer
RekrutacjaFaza 2
- Virginia Cancer Specialists, Fairfax · 11 mi dalej
Signatera-Guided CDK4/6 Inhibitor Therapy in Breast Cancer
Rekrutacja
- Inova, Fairfax · 11 mi dalej
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
RekrutacjaFaza 3
- Virginia Cancer Specialists, Fairfax · 11 mi dalej
A Study of Imlunestrant (LY3484356) in Premenopausal Women With Estrogen Receptor-Positive (ER+) Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Early Breast Cancer
RekrutacjaFaza 2
- Inova Schar Cancer Institute, Fairfax · 11 mi dalej
A Study of JNJ-101684362 (HLD-0117) in Patients With Metastatic Breast Cancer
RekrutacjaFaza 1
- Next Virginia, Fairfax · 11 mi dalej
A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations
RekrutacjaFaza 1/2
- NEXT Oncology, Fairfax · 11 mi dalej
A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of Recurrence
RekrutacjaFaza 3
- Inova Schar Cancer Institute, Fairfax · 11 mi dalej
- Virginia Cancer Specialists, Fairfax · 11 mi dalej
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
RekrutacjaFaza 1
- Virginia Cancer Specialists, Fairfax · 11 mi dalej
A Phase 1/1b Study of IAM1363 in HER2 Cancers
RekrutacjaFaza 1
- NEXT Oncology - Virginia Cancer Specialists, Fairfax · 11 mi dalej
A Study to Evaluate Safety, Tolerability and Preliminary Activity of AGX101 in Participants With Advanced Solid Tumors
RekrutacjaFaza 1
- NEXT Oncology, Fairfax · 11 mi dalej
Study of AMXT 1501 and DFMO in Combination With Standard Therapies in Advanced Solid Tumors
RekrutacjaFaza 1/2
- Virginia Cancer Specialists-Fairfax, Fairfax · 11 mi dalej
Study of ORIC-114 in Patients With Advanced Solid Tumors Harboring an EGFR or HER2 Alteration
RekrutacjaFaza 1/2
- Next Oncology, Fairfax · 11 mi dalej
Phase 3 Study of RLY-2608 + Fulvestrant vs Capivasertib + Fulvestrant as Treatment for Locally Advanced or Metastatic PIK3CA-mutant HR+/HER2- Breast Cancer
RekrutacjaFaza 3
- Virginia Cancer Specialists, PC, Fairfax · 11 mi dalej
A Study of ASP2998 Given by Itself and Given With Standard Therapies in People With Solid Tumors
RekrutacjaFaza 1/2
- NEXT Virginia, Fairfax · 11 mi dalej
The Vanguard Study: Testing a New Way to Screen for Cancer
RekrutacjaZapraszamy zdrowych ochotników
- Inova Schar Cancer Institute, Fairfax · 11 mi dalej
- Inova Fair Oaks Hospital, Fairfax · 11 mi dalej
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
RekrutacjaFaza 3
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi dalej
- Kaiser Permanente-Burke Medical Center, Burke · 11 mi dalej
A Study With NKT5097 for Adults With Advanced/Metastatic Solid Tumors
RekrutacjaFaza 1
- NEXT Virginia, Fairfax · 11 mi dalej
A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
RekrutacjaFaza 1
- NEXT Virginia, Fairfax · 11 mi dalej
A Phase 1 Study of LNCB74 in Advanced Solid Tumors
RekrutacjaFaza 1
- Inova Schar Cancer Institute, Falls Church · 4 mi dalej
Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial
RekrutacjaFaza 3
- Inova Schar Cancer Institute, Fairfax · 11 mi dalej
- Inova Fair Oaks Hospital, Fairfax · 11 mi dalej
Phase 3 Study to Evaluate the Efficacy and Safety of HER2/Neu Peptide GLSI-100 (GP2 + GM-CSF) in HER2/Neu Positive Subjects
RekrutacjaFaza 3
- Virginia Cancer Specialists, Fairfax · 11 mi dalej
Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
RekrutacjaFaza 1/2
- USOR Virginia Cancer Specialists, Fairfax · 11 mi dalej
E-Mindfulness Approaches for Living After Breast Cancer
RekrutacjaFaza 3
- Inova Fairfax Hospital, Falls Church · 4 mi dalej
- Kaiser Permanente Tysons Corner Medical Center, McLean · 5 mi dalej
- Inova Schar Cancer Institute, Fairfax · 11 mi dalej
- i 1 więcej
Study of RGT-490 in Patients With PIK3CA-Mutated Advanced Solid Tumors
RekrutacjaFaza 1
- NEXT Virginia, Fairfax · 11 mi dalej
First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- USO-Virginia Cancer Specialists, PC, Fairfax · 11 mi dalej
Pre-Operative Window of ET to Inform RT Decisions (POWER II)
RekrutacjaFaza 3
- INOVA Schar Cancer, Fairfax · 11 mi dalej
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
RekrutacjaFaza 1/2
- NEXT Oncology Virginia, Fairfax · 11 mi dalej
Phase 1/2 Study of ETX-636 in Participants With Advanced Solid Tumors
RekrutacjaFaza 1/2
- NEXT, Fairfax · 11 mi dalej
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
RekrutacjaFaza 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi dalej
Study of Patritumab Deruxtecan With Other Anticancer Agents in Participants With HER2 Positive Breast Cancer That Has Spread and Cannot Be Surgically Removed (MK-1022-009)
RekrutacjaFaza 1/2
- Inova Schar Cancer Institute ( Site 0051), Fairfax · 11 mi dalej
A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.
RekrutacjaFaza 3
- Virginia Cancer Specialists, PC, Reston · 14 mi dalej
- Virginia Cancer Specialists, Manassas · 22 mi dalej
A Study to Evaluate the Safety and Tolerability of TOS-358 in Women With HR+ HER2- Breast Cancer
RekrutacjaFaza 1
- Virginia Cancer Specialists, Fairfax · 11 mi dalej
Phase I Study of SYS6043 in Patients With Advanced/Metastatic Solid Tumors
RekrutacjaFaza 1
- NEXT Oncology Virginia, Fairfax · 11 mi dalej
A Study of DB-1310 in Advanced/Metastatic Solid Tumors
RekrutacjaFaza 1/2
- NEXT Virginia, Fairfax · 11 mi dalej
A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies
RekrutacjaFaza 1/2
- Virginia Cancer Specialists, Fairfax · 11 mi dalej
Phase 1/2 Dose Finding, Safety and PK Study in Advanced Refractory Solid Tumors
RekrutacjaFaza 1/2
- NEXT, Virginia, Fairfax · 11 mi dalej
First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tumors and in Combination With Endocrine Therapy +/- a CDK4/6 or CDK4 Inhibitor in Patients With Advanced Solid Tumors or Advanced Breast Cancer
RekrutacjaFaza 1
- Inova Schar Cancer Center, Fairfax · 11 mi dalej
- NEXT Virginia, Fairfax · 11 mi dalej
Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of BTX-9341 in Advanced and/or Metastatic Breast Cancer
RekrutacjaFaza 1
- Biotheryx Investigative Site, Fairfax · 11 mi dalej
Badania dla Rak piersi w innych miastach
- New York City, NY134 badań
- Houston, TX126 badań
- Boston, MA111 badań
- Nashville, TN80 badań
- Los Angeles, CA72 badań
- Edison, NJ68 badań
- St. Louis, MO64 badań
- Durham, NC63 badań
- Queens, NY63 badań
- Chicago, IL58 badań
- Philadelphia, PA56 badań
- Dallas, TX55 badań
Inne badania w mieście Arlington
- Niedrobnokomórkowy rak płuca104 badań
- Nowotwór przerzutowy53 badań
- Rak jelita grubego i odbytnicy52 badań
- Nowotwory (wszystkie typy)48 badań
- Rak jajnika46 badań
- Rak płuc41 badań
- Rak endometrium39 badań
- Rak trzustki33 badań
- Rak płaskonabłonkowy głowy i szyi26 badań
- Niedrobnokomórkowy rak płuca23 badań
- Rak piersi potrójnie ujemny20 badań
- Nowotwór żołądka20 badań
Źródło: ClinicalTrials.gov, dane pobrane 5 paź 2026. Każde badanie ustala własne kryteria kwalifikacji; zespół badawczy decyduje, kto może wziąć udział.